New landscapes and horizons in hepatocellular carcinoma therapy

Maria Rita Emma, Maurizio Soresi, Lydia Giannitrapani, Beatrice Belmonte, Giuseppe Montalto, Melchiorre Cervello, Giuseppa Augello, Maria R. Emma, Lydia Giannitrapani, Antonella Cusimano, Shaw M. Akula, Linda S. Steelman, James A. Mccubrey, Giuseppe Montalto, Stephen L. Abrams

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)


Hepatocellular carcinoma (HCC), is the sixth most frequent form of cancer and leads to the fourth highest number of deaths each year. HCC results from a combination of environmental factors and aging as there are driver mutations at oncogenes which occur during aging. Most of HCCs are diagnosed at advanced stage preventing curative therapies. Treatment in advanced stage is a challenging and pressing problem, and novel and well-tolerated therapies are urgently needed. We will discuss further advances beyond sorafenib that target additional signaling pathways and immune checkpoint proteins. The scenario of possible systemic therapies for patients with advanced HCC has changed dramatically in recent years. Personalized genomics and various other omics approaches may identify actionable biochemical targets, which are activated in individual patients, which may enhance therapeutic outcomes. Further studies are needed to identify predictive biomarkers and aberrantly activated signaling pathways capable of guiding the clinician in choosing the most appropriate therapy for the individual patient.
Original languageEnglish
Pages (from-to)3053-3094
Number of pages42
Publication statusPublished - 2020

All Science Journal Classification (ASJC) codes

  • Ageing
  • Cell Biology


Dive into the research topics of 'New landscapes and horizons in hepatocellular carcinoma therapy'. Together they form a unique fingerprint.

Cite this